(Q44846367)

English

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

scientific article published on 19 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

ovarian carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

9

object named as

Mark Clemons

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Marc Tischkowitz

2

object named as

Marc Tischkowitz

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

10

object named as

Blake Gilks

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

author name string

Karen A Gelmon

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Helen Mackay

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Kenneth Swenerton

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

André Robidoux

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Katia Tonkin

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Hal Hirte

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

David Huntsman

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Rinat Yerushalmi

11

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Euan Macpherson

12

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

James Carmichael

13

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Amit Oza

14

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

publication date

19 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

12

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

9

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

852-861

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

BRCA1 and BRCA2 and the genetics of breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast cancer genetics: what we know and what we need

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The contribution of BRCA1 and BRCA2 to ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Triple negative breast cancer: unmet medical needs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

PARP inhibition: PARP1 and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970214-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70214-5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

http://europepmc.org/abstract/MED/21862407

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44846367&oldid=2053240002"